Loading clinical trials...
Loading clinical trials...
A Long-Term Follow-Up Study of Participants Treated With the Lentiviral-Based Genetically Modified, Autologous Cell Product, AGT103-T
Long-term follow-up of study subjects who received AGT103-T product in HIV study. The AGT103-T is genetically modified cells that resist infection with HIV causing a depletion of HIV in HIV-infected study participants.
The primary objective of this study is to monitor study participant who receive the genetically modified gag specific CD4 T cells for the long term adverse event, evaluate sustained impact on immunity and the persistence of vector modified CD4 T cells.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Georgetown University
Washington D.C., District of Columbia, United States
Washington Health Institute
Washington D.C., District of Columbia, United States
Start Date
August 29, 2022
Primary Completion Date
May 23, 2038
Completion Date
September 29, 2038
Last Updated
December 2, 2022
7
ESTIMATED participants
Gene modified therapy
BIOLOGICAL
Lead Sponsor
American Gene Technologies International Inc.
NCT01875588
NCT07071623
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04929028